Leerink Partnrs Analysts Decrease Earnings Estimates for BMY

Key Points

• Analysts at Leerink Partnrs have decreased their Q3 2025 earnings estimates for Bristol Myers Squibb to $1.47 per share, down from $1.66.
• The biopharmaceutical company reported a Q2 earnings per share of $1.46, exceeding the consensus estimate of $1.07, along with revenue of $12.27 billion.
• Bristol Myers Squibb has announced a quarterly dividend of $0.62 per share to be paid on November 3, with a yield of 5.7%.

Bristol Myers Squibb Company (NYSE:BMY - Free Report) - Investment analysts at Leerink Partnrs lowered their Q3 2025 earnings estimates for shares of Bristol Myers Squibb in a research note issued on Monday, October 13th. Leerink Partnrs analyst D. Risinger now forecasts that the biopharmaceutical company will earn $1.47 per share for the quarter, down from their previous estimate of $1.66. The consensus estimate for Bristol Myers Squibb's current full-year earnings is $6.74 per share. Leerink Partnrs also issued estimates for Bristol Myers Squibb's FY2028 earnings at $5.86 EPS.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.07 by $0.39. The company had revenue of $12.27 billion for the quarter, compared to analyst estimates of $11.32 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. Bristol Myers Squibb's revenue was up .6% compared to the same quarter last year. During the same period last year, the company posted $2.07 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS.

Several other equities analysts have also issued reports on the company. Morgan Stanley reiterated a "hold" rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Weiss Ratings reissued a "hold (c-)" rating on shares of Bristol Myers Squibb in a research report on Tuesday. Daiwa America cut shares of Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 5th. Citigroup reaffirmed a "neutral" rating on shares of Bristol Myers Squibb in a report on Monday. Finally, Daiwa Capital Markets downgraded Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 target price on the stock. in a research report on Tuesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and fifteen have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $57.14.

Bristol Myers Squibb Trading Up 0.6%

Shares of NYSE:BMY opened at $43.82 on Wednesday. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54. The company has a market capitalization of $89.18 billion, a PE ratio of 17.67, a P/E/G ratio of 2.25 and a beta of 0.33. Bristol Myers Squibb has a 12-month low of $42.96 and a 12-month high of $63.33. The business's fifty day simple moving average is $46.18 and its 200-day simple moving average is $47.81.

Hedge Funds Weigh In On Bristol Myers Squibb

Several large investors have recently made changes to their positions in the company. Harel Insurance Investments & Financial Services Ltd. purchased a new position in shares of Bristol Myers Squibb in the 1st quarter valued at about $31,000. Trifecta Capital Advisors LLC purchased a new stake in shares of Bristol Myers Squibb in the second quarter valued at approximately $25,000. Accent Capital Management LLC acquired a new position in shares of Bristol Myers Squibb during the 1st quarter worth approximately $33,000. Darwin Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb during the 2nd quarter valued at approximately $25,000. Finally, CBIZ Investment Advisory Services LLC grew its stake in Bristol Myers Squibb by 66.0% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company's stock valued at $35,000 after acquiring an additional 231 shares during the period. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP David V. Elkins sold 56,000 shares of the company's stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the sale, the executive vice president owned 167,379 shares in the company, valued at $7,922,048.07. This represents a 25.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.07% of the company's stock.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Investors of record on Friday, October 3rd will be given a dividend of $0.62 per share. The ex-dividend date is Friday, October 3rd. This represents a $2.48 dividend on an annualized basis and a yield of 5.7%. Bristol Myers Squibb's payout ratio is currently 100.00%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.